Pfizer (PFE) yields nearly 7% as COVID drugs crater, while Merck (MRK) compounds at 66% one-year gains with a leaner 3% payout.
Pfizer runs 20 pivotal trials in 2026 targeting obesity and oncology, with a Vyndamax patent extension to 2031 protecting dividend coverage.
It sounds nuts, but SoFi1 is giving new Active Invest users up to $3,000 in stock for a limited time, and all it takes is a $50 deposit to get started.2 See for yourself (Sponsor)
Pfizer (NYSE:PFE) and Merck (NYSE:MRK) refreshed the dividend debate with their latest quarterly reports.
Pfizer defends one of Big Pharma's fattest yields while its COVID franchise fades. Merck absorbs multi-billion dollar deal charges to reload a pipeline behind Keytruda. Two payouts, two very different risk profiles for income investors.
#NYSE #yields #Dividend
Pfizer runs 20 pivotal trials in 2026 targeting obesity and oncology, with a Vyndamax patent extension to 2031 protecting dividend coverage.
It sounds nuts, but SoFi1 is giving new Active Invest users up to $3,000 in stock for a limited time, and all it takes is a $50 deposit to get started.2 See for yourself (Sponsor)
Pfizer (NYSE:PFE) and Merck (NYSE:MRK) refreshed the dividend debate with their latest quarterly reports.
Pfizer defends one of Big Pharma's fattest yields while its COVID franchise fades. Merck absorbs multi-billion dollar deal charges to reload a pipeline behind Keytruda. Two payouts, two very different risk profiles for income investors.
#NYSE #yields #Dividend
1 day ago
